Synaptogenix Inc (SNPX)

[Cyosol]

It's a 6 month trial (10 months for full data) with about 40+ completer patients in each group.

If the drug works as expected, the results should be crystal clear and remove most doubts about its efficacy, and then the question is:

How much do you think a statistically significant improvement in moderately severe AD patients is worth? Would you look at a company like Cassava and say it's worth less than that? Would you sell shares at a $500 million valuation because you think it's not worth $1 billion?

Don't forget that it would be a positive signal for the other diseases they're pursuing too.